philosophy-imageThe New Ferring Oncology Division

In the US, 80,000 people are diagnosed with bladder cancer annually1.

Ferring is building its US Oncology team in preparation to commercialize nadofaragene firadenovec  (rAd-IFN/Syn3), a novel gene-mediated therapy in Phase 3 development to potentially treat high-grade non-muscle invasive bladder cancer (NMIBC) patients, who are unresponsive to Bacillus Calmette-Guérin (BCG) therapy. The US FDA has granted Fast Track and Breakthrough Therapy designation for nadofaragene firadenovec.

See current job openings


Ferring Oncology in the News

A Humanity Driven Focus (PharmaVOICE, August 01, 2019)

Ferring Pharmaceuticals Appoints New Cancer Division Lead (PMLiVE, January 29, 2019)

Ferring Makes Foray Into Gene Therapy With FKD Pact (Scrip, May 03, 2018)

Ferring Commits to US Oncology and Cutting-Edge Research (The PharmaLetter, May 03, 2018)

Ferring Gains Option for Bladder Cancer Gene Therapy (BioCentury, May 03, 2018)

Ferring Gains Option to FKD’s Phase III Bladder Cancer Gene Therapy Candidate (GEN, May 03, 2018)

Ferring Oncology News Releases

January 23, 2019
Ferring Pharmaceuticals appoints Sophie Opdyke to lead its new U.S. oncology division

May 03, 2018
Ferring signs global agreement to commercialise novel gene therapy for bladder cancer patients

1. NIH, Cancer Stat Facts: Bladder Cancer, accessed 6/20/19

This site contains material about Ferring Pharmaceuticals Inc. (hereinafter "Ferring") and its various products that may be of interest to Ferring's employees and customers, as well as to members of the health care community and the general public. Please feel free to browse this web site. Your access and use of the information contained herein is subject to the following terms and conditions and all applicable laws. By accessing and browsing this web site, you accept, without limitation or qualification, these terms and conditions and acknowledge that they supersede any other agreement between you and Ferring.

All information on this site is intended for US audiences only.

CERVIDIL, EUFLEXXA, FIRMAGON, NOCDURNA, ZOMACTON, and PREPOPIK are registered trademarks of Ferring B.V. CLENPIQ is a trademark of Ferring B.V.

©2008-2018 Ferring Pharmaceuticals.  GC/1722/2014/US(4)